Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lonaprisan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Lonaprisan (ZK 230211, BAY86-5044) | DRUG | 25 mg daily oral treatment |
Inclusion Criteria: * Postmenopausal women defined as: aged \>/= 50 years with amenorrhea for at least 12 months or aged \< 50 years with 6 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) level within postmenopausal range (\> 40 mIU/ml) or having undergone bilateral oophorec...
Top 20 of 87 competitors
Lonaprisan was studied for the treatment of metastatic breast cancer in postmenopausal women. It is an investigational small molecule developed by Bayer AG and has been evaluated in a Phase 2 clinical trial in this indication. It is not an approved therapy.
Lonaprisan targets the progesterone receptor, also known as PGR. It acts as a progesterone receptor antagonist, meaning it blocks the receptor's activity. This mechanism was the basis for its investigation in hormone-sensitive metastatic breast cancer.
Lonaprisan is developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer sponsored the clinical trial of Lonaprisan in metastatic breast cancer.
Lonaprisan is in Phase 2 development. It has completed one Phase 2 clinical trial in metastatic breast cancer. It is an investigational drug and is not FDA approved.
Lonaprisan was evaluated in the Phase 2 trial NCT00555919, titled ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer. The trial enrolled 68 participants across ten European countries and is completed. No active trials are ongoing.
Yes. Lonaprisan is also known as ZK 230211 and BAY86-5044. These are alternative names for the same investigational compound developed by Bayer AG.